Multimerization improves targeting of peptide Radio-Pharmaceuticals

Current Pharmaceutical Design

Volumn 18, Issue 17, 2012, Pages 2501-2516

  Carlucci, Giuseppe ^a   Ananias, Hildo J K ^a   Yu, Zilin ^a   van de Wiele, Christophe ^b   Dierckx, Rudi A ^a,b   de Jong, Igle J ^a   Elsinga, Philip H ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Avidity; Binding; Cooperativity; Ligand design; Multimerization; Nanotechnology; Nuclear imaging; Valency

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; ACETIC ACID DERIVATIVE; DENDRIMER; GADOTERIC ACID; HETERODIMER; HOMODIMER; MACROGOL; NEUROTENSIN[8-13]; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CYCLOADDITION; DIELS ALDER REACTION; ENTROPY; ISOTOPE LABELING; LIGAND BINDING; NANOTECHNOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN MULTIMERIZATION; RECEPTOR BINDING; RING OPENING METATHESIS POLYMERIZATION; STAUDINGER REACTION; THERMODYNAMICS;

EID: 84860469865     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128112092501     Document Type: Article

References (98)

1. Mammen M, Choi S-K, Whitesides GM. Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multiva- lent Ligands and Inhibitors. Angewandte Chemie International Edition 1998; 37(20): 2754-94.
2. Kramer RH, Karpen JW. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 1998; 395(6703): 710-3.
3. Kiessling LL, Strong LE, Gestwicki JE. Chapter 29. Principles for multivalent ligand design. In: Annual Reports in Medicinal Chemistry. Academic Press 2000. p. 321-30.
4. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ. Hitting multiple targets with multimeric ligands. Expert Opinion on Therapeut Targets 2004; 8(6): 565-86.
5. Mulder A, Huskens J, Reinhoudt DN. Multivalency in supramolecular chemistry and nanofabrication. Organic Biomolecular Chem 2004; 2(23): 3409-24.
6. Vance D, Shah M, Joshi A, Kane RS. Polyvalency: a promising strategy for drug design. Biotechnol bioengineering 2008; 101(3): 429-34.
7. Dijkraaf I, Wester HJ. Peptides, Multimers and Polymers. Molecular Imaging II 2008; 185/2: 61-92.
8. Podtelezhnikov AA, Mao C, Seeman NC, Vologodskii A. Multimerization- Cyclization of DNA Fragments as a Method of Conformational Analysis. Biophysical J 2000; 79(5): 2692-704.
9. Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS letters 1991; 291(1): 50-4.
10. Sano K, Asanuma-Date K, Arisaka F, Hattori S, Ogawa H. Changes in glycosylation of vitronectin modulate multimerization and collagen binding during liver regeneration. Glycobiology 2007; 17(7): 784-94.
11. Colman PM, Air GM, Webster RG, et al. How antibodies recognize virus proteins. Immunol today 1987; 8(11): 323-6.
12. Imai M, Mizuno T, Kawasaki K. Membrane fusion by single influenza hemagglutinin trimers: Kinetic evidence from image analysis of hemagglutinin-reconstituted vesicles. J Biological Chem 2006;
13. Pieters RJ. Intervention with bacterial adhesion by multivalent carbohydrates. Medicinal Res Rev 2007; 27(6): 796-816.
14. Tweedle MF. Adventures in multivalency, the Harry S. Fischer memorial lecture CMR 2005; Evian, France. Contrast Media Mol Imaging 2006; 1(1): 2-9.
15. Haywood AM. Virus receptors: binding, adhesion strengthening, and changes in viral structure. J Virology 1994; 68(1): 1-5.
16. Wängler C, Maschauer S, Prante O, Schäfer M, Schirrmacher R, Bartenstein P, et al. Multimerization of cRGD peptides by click chemistry: synthetic strategies, chemical limitations, and influence on biological properties. Chembiochem: a European J chemical Biol 2010; 11(15): 2168-81.
17. Gestwicki JE, Strong LE, Cairo CW, Boehm FJ, Kiessling LL. Cell Aggregation by Scaffolded Receptor Clusters. Chemistry Biol 2002; 9(2): 163-9.
18. Bongrand P. Ligand-receptor interactions. Reports on Progress in Physics 1999; 62(6): 921.
19. [Schwyzer R. 100 years lock-and-key concept: are peptide keys shaped and guided to their receptors by the target cell membrane? Biopolymers 1995 Jan; 37(1): 5-16.
20. Wester H-J, Kessler H. Molecular targeting with peptides or peptide- polymer conjugates: just a question of size? J nuclear medicine: official publication, Society Nuclear Med 2005; 46(12): 1940-5.
21. Whitesides GM, Krishnamurthy VM. Designing ligands to bind proteins. Quarterly Rev Biophysics 2005; 38(04): 385-95.
22. Kitov PI, Bundle DR. On the Nature of the Multivalency Effect: A Thermodynamic Model. J Am Chemical Society 2003; 125(52): 16271-84.
23. [Krishnamurthy VM, Estroff LA, Whitesides GM. Multivalency in Ligand Design. Fragment-based Approaches in Drug Discovery. 11-53.
24. Bellelli A. Hemoglobin and Cooperativity: Experiments and Theories. Current Protein Peptide Science 2010; 11(1): 2-36.
25. Kane RS. Thermodynamics of Multivalent Interactions: Influence of the Linker. Langmuir 2010; 26(11): 8636-40.
26. Gauthier MA, - Klok H-A. Peptide/protein-polymer conjugates: synthetic strategies and design concepts. Chemical Communications 2008; (23): 2591-611.
27. Benedetti E, Morelli G, Accardo A, Mansi R, Tesauro D, Aloj L. Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals. Bio Drugs 2004; 18(5): 279-95.
28. Gotthardt M, Boermann OC, Behr TM, Béhé MP, Oyen WJG. Development and Clinical Application of Peptide-Based Radiopharmaceuticals. Current pharmaceutical design 2004; 10(24): 2951-63.
29. Olafsen T, Wu AM. Antibody Vectors for Imaging. Antibodies and Peptides in Nuclear Medicine Imaging Therapy 2010; 40(3): 167-81.
30. Jayaraman N. Multivalent ligand presentation as a central concept to study intricate carbohydrate-protein interactions. Chemical Society Rev 2009; 38(12): 3463-83.
31. Blok D, Feitsma RIJ, Vermeij P, Pauwels EJK. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nuclear Med 1999; 26(11): 1511.
32. Brower V. Beyond FDG: Many Molecular Imaging Agents Are in Development. JNCI: J Nat Cancer Institute 2011; 103(1): 13-5.
33. Lee Y-S. Radiopharmaceuticals for molecular imaging. Open Nuclear Med J 2010; 2: 178-85.
34. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. European J Nuclear Med Mol Imaging 2003; 30(3): 463-9.
35. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1(8632): 242-4.
36. [Ahlgren S TV. Radionuclide Molecular Imaging Using Affibody Molecules. Curr Pharm Biotechnol. 11(6): 581-9.
37. Tolmachev V, Velikyan I, Sandström M, Orlova A. A HER2- binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nuclear Med molecular imaging 2010; 37(7): 1356-67.
38. Tran TA, Rosik D, Abrahmsén L, et al. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. European J nuclear medicine molecular imaging 2009; 36(11): 1864-73.
39. Kiessling LL, Gestwicki JE, Strong LE. Synthetic Multivalent Ligands as Probes of Signal Transduction. Angewandte Chemie Int Edition 2006; 45(15): 2348-68.
40. Boas U, Heegaard PMH. Dendrimers in drug research. Chem Society Rev 2004; 33(1): 43-63.
41. Dijkgraaf I, Yim C-B, Franssen GM, et al. PET imaging of αvβ3 integrin expression in tumours with 68Ga-labelled mono-, di- and tetrameric RGD peptides. European J nuclear medicine molecular imaging 2011; 38(1): 128-37.
42. Shewmake TA, Solis FJ, Gillies RJ, Caplan MR. Effects of Linker Length and Flexibility on Multivalent Targeting. Biomacromolecules 2008; 9(11): 3057-64.
43. Vance D, Martin J, Patke S, Kane RS. The design of polyvalent scaffolds for targeted delivery. Adv drug delivery Rev 2009; 61(11): 931-9.
44. Raju N, Ranganathan RS, Tweedle MF, Swenson RE. A new dendrimer scaffold for preparing dimers or tetramers of biologically active molecules. Tetrahedron letters 2005; 46(9): 1463-5.
45. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP. Liposomes Modified with Cyclic RGD Peptide for Tumor Targeting. J drug targeting 2004; 12(5): 7-264.
46. Jung H, Robison AD, Cremer PS. Multivalent ligand-receptor binding on supported lipid bilayers. J structural Biol 2009; 168(1): 90-4.
47. Gillies ER, Fréchet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug discovery today 2005; 10(1): 35-43.
48. Satija J Jain NK. GU. Pharmaceutical and biomedical potential of surface engineered dendrimers. Critical Rev in Therapeutic Carrier Systems 2007; 24(3): 257-306.
49. Mullen DG, McNerny DQ, Desai A, et al. Design, synthesis, and biological functionality of a dendrimer-based modular drug delivery platform. Bioconjugate chemistry 2011; 22(4): 679-89.
50. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Delivery Rev 2008; 60(9): 1037-55.
51. Tomalia DA Svenson S. RLA. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochemical society transactions 2007; 35(1): 61-7.
52. Kowalczyk W, Monsó M, de la Torre BG, Andreu D. Synthesis of multiple antigenic peptides (MAPs)-strategies and limitations. J peptide science??: an official publication of the European Peptide Society 2011; 17(4): 247-51.
53. Cheng Y, Xu T. The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs. European J medicinal chemistry 2008; 43(11): 2291-7.
54. Talanov VS, Regino CAS, Kobayashi H, Bernardo M, Choyke PL, Brechbiel MW. Dendrimer-Based Nanoprobe for Dual Modality Magnetic Resonance and Fluorescence Imaging. Nano Letters 2006; 6(7): 1459-63.
55. Boswell CA, Eck PK, Regino CAS, et al. Synthesis, Characterization, and Biological Evaluation of Integrin αvβ3-Targeted PAMAM Dendrimers. Molecular Pharmaceutics 2008; 5(4): 527-39.
56. Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker James R. J. Tumor angiogenic vasculature targeting with PAMAM dendrimer- RGD conjugates. Chemical Communications 2005; (46): 5739-41.
57. Lim RKV, Lin Q. NIH Public Access. New York 2011; 53(1): 61-70.
58. Kahne D. Combinatorial approaches to carbohydrates. Current opinion in chemical Biol 1997; 1(1): 130-5.
59. Kent SBH. Total chemical synthesis of proteins. Chemical Society Rev 2009; 38(2): 338-51.
60. Clark RJ, Craik DJ. Invited reviewnative chemical ligation applied to the synthesis and bioengineering of circular peptides and proteins. Peptide Science 2010; 94(4): 414-22.
61. Kimmerlin T, Seebach D. "100 years of peptide synthesis": ligation methods for peptide and protein synthesis with applications to betapeptide assemblies. The J peptide research??: official J Am Peptide Society 2005; 65(2): 229-60.
62. David R, Richter MPO, Beck-Sickinger A. Method and applications. European J Biochemistry 2004; 271(4): 663-77.
63. Kochendoerfer GG, Kent SB. Chemical protein synthesis. Current opinion in chemical Biol 1999; 3(6): 665-71.
64. Wallace CJA. Peptide ligation and semisynthesis. Current opinion in biotechnology 1995; 6(4): 403-10.
65. Xiao J, Hamilton BS, Tolbert TJ. Synthesis of N-Terminally Linked Protein and Peptide Dimers by Native Chemical Ligation. Bioconjugate chemistry 2010; 21(11): 1943-7.
66. Hofmann RM, Muir TW. Recent advances in the application of expressed protein ligation to protein engineering. Current opinion in biotechnology 2002; 13(4): 297-303.
67. Köhn M, Breinbauer R. The Staudinger ligation-a gift to chemical biology. Angewandte Chemie (International ed. in English) 2004; 43(24): 3106-16.
68. Nilsson BL, Kiessling LL, Raines RT. Staudinger Ligation: A Peptide from a Thioester and Azide. Organic letters 2000; 2(13): 1939-41.
69. [Hooks JC, Matharage JP, Udugamasooriya DG. Development of homo- and hetero-multimers of lung cancer specific peptoids. Peptide Science 2011;: n/a-n/a.
70. van Baal I, Malda H, Synowsky SA, et al. Multivalent peptide and protein dendrimers using native chemical ligation. Angewandte Chemie (International ed. in English) 2005; 44(32): 5052-7.
71. Haubner R, Wester H-J. Radiolabeled Tracers for Imaging of Tumor Angiogenesis and Evaluation of Anti-Angiogenic Therapies. Current pharmaceutical design 2004; 10(13): 1439-55.
72. Liu W, Hao G, Long M A, Anthony T, Hsieh J-T, Sun X. Imparting multivalency to a bifunctional chelator: a scaffold design for targeted PET imaging probes. Angewandte Chemie (International ed. in English) 2009; 48(40): 7346-9.
73. Dijkgraaf I, Rijnders AY, Soede A, et al. Synthesis of DOTAconjugated multivalent cyclic-RGD peptide dendrimers via 1,3- dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Organic Biomolecular Chem 2007; 5(6): 935-44.
74. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L. Multivalent Effects of RGD Peptides Obtained by Nanoparticle Display. J med chem 2006; 49(20): 6087-93.
75. Huskens J. Multivalent interactions at interfaces. Current opinion in chemical Biol 2006; 10(6): 537-43.
76. Da Pieve C, Williams P, Haddleton DM, Palmer RMJ, Missailidis S. Modification of Thiol Functionalized Aptamers by Conjugation of Synthetic Polymers. Bioconjugate chemistry 2010; 21(1): 169-74.
77. Merritt EA, Zhang Z, Pickens JC, Ahn M, Hol WGJ, Fan E. Characterization and Crystal Structure of a High-Affinity Pentavalent Receptor-Binding Inhibitor for Cholera Toxin and E. coli Heat- Labile Enterotoxin. J Am Chemical Society 2002; 124(30): 8818-24.
78. Tam JP, Yu Q, Miao Z. Orthogonal ligation strategies for peptide and protein. Peptide Science 1999; 51(5): 311-32.
79. Xiaoyuan C, Tohme M, Park R, Hou Y, Bading J, Conti P. Micro- PET Imaging of αvβ3-Integrin Expression with 18F-Labeled Dimeric RGD Peptide. Molecular Imaging 2004; 3(2): 96-104.
80. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solidphase peptide synthesis and chemoselective oxime ligation. Chemistry (Weinheim an der Bergstrasse, Germany) 2003; 9(12): 2717-25.
81. Poethko T, Schottelius M, Thumshirn G, et al. Chemoselective preconjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta 2004; 92(4-6): 317-27.
82. Liu Z, Yan Y, Liu S, Wang F, Chen X. 18F, 64Cu, and 68Ga Labeled RGD-Bombesin Heterodimeric Peptides for PET Imaging of Breast Cancer. Bioconjugate chemistry 2009; 20(5): 1016-25.
83. Dijkgraaf I, Liu S, Kruijtzer JAW, et al. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nuclear medicine and Biol 2007; 34(1): 29-35.
84. Pillai R, Marinelli ER, Swenson RE. A flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups. Peptide Science 2006; 84(6): 576-85.
85. Liu Z, Li Z-B, Cao Q, Liu S, Wang F, Chen X. Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer. J Nuclear Med 2009; 50(7): 1168-77.
86. Li Z-B, Chen K, Chen X. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression. Eur J Nuclear Med Mol Imaging 2008; 35(6): 1100-8.
87. Handl HL, Sankaranarayanan R, Josan JS, et al. Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjugate chemistry 2007; 18(4): 1101-9.
88. Yan Y, Chen K, Yang M, Sun X, Liu S, Chen X. A new 18Flabeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 2010;: 1-9.
89. Hultsch C, Berndt M, Bergmann R, Wuest F. Radiolabeling of multimeric neurotensin(8-13) analogs with the short-lived positron emitter fluorine-18. Applied Radiation and Isotopes 2007; 65(7): 818-26.
90. Yim C, van der Wildt B, Dijkgraaf I, Joosten L, Eek A, Versluis C, et al. Spacer effects on in vivo properties of DOTA-conjugated dimeric [Tyr3]octreotate peptides synthesized by a "Cu(I)-click" and "sulfo-click" ligation method. Chembiochem: a European J chemical Biol 2011 Mar 21; 12(5): 750-60.
91. Turnbull WB, Stoddart JF. Design and synthesis of glycodendrimers. Rev in Molecular Biotechnology 2002; 90(3-4): 231-55.
92. Oren EE, Notman R, Kim IW, et al. Probing the Molecular Mechanisms of Quartz-Binding Peptides. Langmuir 2010; 26(13): 11003-9.
93. Seker UOS, Wilson B, Sahin D, Tamerler C, Sarikaya M. Quantitative Affinity of Genetically Engineered Repeating Polypeptides to Inorganic Surfaces. Biomacromolecules 2009; 10(2): 250-7.
94. Chang CH Goldenberg DM. REA. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clinical cancer research 2007; 13(18): 5586-91.
95. Rana S, Yeh YC, Rotello VM. Engineering the nanoparticleprotein interface: applications and possibilities. Current opinion in chemical Biol 2010; 14(6): 828-34.
96. Bowman M-C, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Society 2008; 130(22): 6896-7.
97. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5(3): 161-71.
98. Yang XC, Samanta B, Agasti SS, et al. Drug Delivery Using Nanoparticle-Stabilized Nanocapsules. Angewandte Chemie Int Edition 2011; 50(2): 477-81.